{"schema_version":"secwatch.filing_event.v1","accession":"0000899923-23-000052","form_type":"8-K","ticker":"MYGN","cik":"0000899923","company_name":"MYRIAD GENETICS INC","filed_at":"2023-08-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.969805+00:00","generated_at":"2026-06-12T10:39:19.276822+00:00","sec_items":["2.02","3.02","8.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Myriad Genetics Q2 revenue $183.5M, settles securities class action for $77.5M","bullets":["Q2 revenue $183.5M, up 2% YoY; diluted GAAP EPS $(1.42), adjusted EPS $(0.08).","Test volume grew 38% YoY (17% ex-SneakPeek); hereditary cancer volume up 20% YoY.","Agreed to settle securities class action for $77.5M: $20M cash in Q3 2023, remainder in cash or stock by Q1 2024.","Reaffirmed FY2023 revenue guidance $730-750M; adjusted EPS loss $(0.36)-(0.24); targeting positive adjusted profitability in Q4.","Established new $90M asset-based credit facility (option to $115M); ended Q2 with $127.8M cash."],"urls":{"canonical":"https://secwatch.observer/filing/0000899923-23-000052","json":"https://secwatch.observer/filing/0000899923-23-000052.json","markdown":"https://secwatch.observer/filing/0000899923-23-000052.md","text":"https://secwatch.observer/filing/0000899923-23-000052.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/899923/000089992323000052/0000899923-23-000052-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/899923/000089992323000052/mygn-20230803.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T10:39:19.276822+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"71eca2035164e8771606aea8d157417a45ae6b73","claim":"MYRIAD GENETICS INC reported second quarter ended June 30, 2023 results: revenue $183.5 million, EPS $(1.42). Guidance reaffirmed.","evidence_excerpt":"volumes grew 23% year-over-year. ▪ Prenatal test volumes grew 12% year-over-year, excluding contributions from the SneakPeek Early Gender DNA Test. • Second quarter revenue of $183.5 million, grew 2% year-over-year, inclusive of a $11.7 million change of estimate in the second quarter of 2022 versus an immaterial amount in the current quarter. Excluding these change","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/899923/000089992323000052/0000899923-23-000052-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter ended June 30, 2023"},{"label":"Revenue","value":"$183.5 million"},{"label":"EPS","value":"$(1.42)"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}